Prothrombin complex concentrates were associated with a lower incidence of hematoma growth (19%) compared to fresh frozen plasma (33%) and vitamin K (50%) in OAT-associated intracerebral hemorrhage.
Observational (n=55)
Do prothrombin complex concentrates reduce hematoma growth and improve outcomes in patients with oral anticoagulant-associated intracerebral hemorrhage compared to fresh frozen plasma or vitamin K?
In patients with OAT-associated intracerebral hemorrhage, PCC administration is associated with a reduced incidence and extent of hematoma growth compared to FFP and VAK, likely due to more rapid INR reversal.
Absolute Event Rate: 19% vs 33%
BACKGROUND AND PURPOSE: Intracerebral hemorrhage (ICH) is the most serious and potentially fatal complication of oral anticoagulant therapy (OAT). Still, there are no universally accepted treatment regimens for patients with OAT-ICH, and randomized controlled trials do not exist. The aim of the present study was to compare the acute treatment strategies of OAT-associated ICH using vitamin K (VAK), fresh frozen plasma (FFP), and prothrombin complex concentrates (PCCs) with regard to hematoma growth and outcome. METHODS: In this retrospective study, a total of 55 treated patients were analyzed. Three groups were compared by reviewing the clinical, laboratory, and neuroradiological parameters: (1) patients who received PCCs alone or in combination with FFP or VAK (n=31), (2) patients treated with FFP alone or in combination with VAK (n=18), and (3) patients who received VAK as a monotherapy (n=6). The end points of early hematoma growth and outcome after 12 months were analyzed including multivariate analysis. RESULTS: Hematoma growth within 24 hours occurred in 27% of patients. Incidence and extent of hematoma growth were significantly lower in patients receiving PCCs (19%/44%) compared with FFP (33%/54%) and VAK (50%/59%). However, this effect was no longer seen between PCC- and FFP-treated patients if international normalized ratio (INR) was completely reversed within 2 hours after admission. The overall outcome was poor (modified Rankin scale 4 to 6 in 77%). Predictors for hematoma growth were an increased INR after 2 hours, whereas administration of PCCs was significantly protective in multivariate analyses. Predictors for a poor outcome were age, baseline hematoma volume, and occurrence of hematoma growth. CONCLUSIONS: Overall, PCC was associated with a reduced incidence and extent of hematoma growth compared with FFP and VAK. This effect seems to be related to a more rapid INR reversal. Randomized controlled trials are needed to identify the most effective acute treatment regimen for lasting INR reversal because increased levels of INR were predisposing for hematoma enlargement.
Huttner et al. (Fri,) conducted a observational in Intracerebral hemorrhage related to oral anticoagulant therapy (n=55). Prothrombin complex concentrates (PCCs) vs. Fresh frozen plasma (FFP) and/or Vitamin K (VAK) was evaluated on Incidence of hematoma growth within 24 hours. Prothrombin complex concentrates were associated with a lower incidence of hematoma growth (19%) compared to fresh frozen plasma (33%) and vitamin K (50%) in OAT-associated intracerebral hemorrhage.